Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy

Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy

Background Immune checkpoint inhibitors (ICI) have radically changed cancer therapy, but most patients with cancer are unresponsive or relapse after treatment. MK-5890 is a CD27 agonist antibody intended to complement ICI therapy. CD27 is a member of the tumor necrosis factor receptor superfamily th...

Full description

Bibliographic Details
Main Authors: David Rosen, Laurence Fayadat-Dilman, Yiwei Zhang, Konstantin Dobrenkov, Elliot Chartash, Richard Wnek, Smita Mauze, Hans van Eenennaam, Judith Stammen-Vogelzangs, Ying Yu, Marco Guadagnoli, Lars Guelen, Thierry O Fischmann, Jerelyn Wong, Nikolina Bąbała, Jozef Wagenaars, Veronica Juan, Winnie Prosise, Maurice Habraken, Imke Lodewijks, Danling Gu, Jeanne Baker, David Lutje Hulsik, Lilian Driessen-Engels, Dan Malashock, Joost Kreijtz, Astrid Bertens, Evert de Vries, Astrid Bovens, Arne Bramer, Sean Troth, Svetlana Sadekova, Andrea van Elsas, Jason K Cheung, Jannie Borst, Amy M Beebe
Format: Article
Language:English
Published: BMJ Publishing Group 2022-09-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/9/e005049.full

Internet

https://jitc.bmj.com/content/10/9/e005049.full

Similar Items